PT3044229T - Péptidos para utilização no tratamento de mucosite oral - Google Patents

Péptidos para utilização no tratamento de mucosite oral

Info

Publication number
PT3044229T
PT3044229T PT148442767T PT14844276T PT3044229T PT 3044229 T PT3044229 T PT 3044229T PT 148442767 T PT148442767 T PT 148442767T PT 14844276 T PT14844276 T PT 14844276T PT 3044229 T PT3044229 T PT 3044229T
Authority
PT
Portugal
Prior art keywords
analogs
treatment
oral mucositis
novel peptides
peptides
Prior art date
Application number
PT148442767T
Other languages
English (en)
Original Assignee
Soligenix Inc
Oreola Donini
Rozek Annett
Lee Jackson
North John
Abrams Michael J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soligenix Inc, Oreola Donini, Rozek Annett, Lee Jackson, North John, Abrams Michael J filed Critical Soligenix Inc
Publication of PT3044229T publication Critical patent/PT3044229T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT148442767T 2013-09-13 2014-08-11 Péptidos para utilização no tratamento de mucosite oral PT3044229T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361877767P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
PT3044229T true PT3044229T (pt) 2023-12-11

Family

ID=52666140

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148442767T PT3044229T (pt) 2013-09-13 2014-08-11 Péptidos para utilização no tratamento de mucosite oral

Country Status (25)

Country Link
US (2) US9850279B2 (pt)
EP (1) EP3044229B1 (pt)
JP (2) JP6645968B2 (pt)
KR (3) KR102483333B1 (pt)
CN (1) CN105722852B (pt)
AU (3) AU2014318247B2 (pt)
BR (1) BR112016005557B1 (pt)
CA (1) CA2923553C (pt)
DK (1) DK3044229T3 (pt)
ES (1) ES2965906T3 (pt)
FI (1) FI3044229T3 (pt)
HK (1) HK1221960A1 (pt)
HR (1) HRP20231652T1 (pt)
HU (1) HUE066502T2 (pt)
IL (1) IL244573B (pt)
LT (1) LT3044229T (pt)
MX (1) MX2016003092A (pt)
MY (1) MY177930A (pt)
NZ (2) NZ718534A (pt)
PL (1) PL3044229T3 (pt)
PT (1) PT3044229T (pt)
RU (1) RU2668963C2 (pt)
SG (1) SG11201601891XA (pt)
WO (1) WO2015038264A1 (pt)
ZA (2) ZA201601967B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9808438B2 (en) * 2015-11-09 2017-11-07 Enzychem Lifesciences Corporation Method for treating mucositis
GB201711183D0 (en) 2017-07-12 2017-08-23 Smith & Nephew Antimicrobial or wound care materials, devices and uses
US20200108098A1 (en) * 2018-02-23 2020-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Anti-cd83 chimeric antigen receptor expressing t regulatory cells
KR102192471B1 (ko) * 2019-10-18 2020-12-17 주식회사 인코스팜 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물
AU2021354766A1 (en) 2020-09-30 2023-05-11 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
CN117858717A (zh) 2021-08-30 2024-04-09 联合化学实验室有限公司 用于治疗炎症性疾病的蛋白质组合物
CN115944708A (zh) * 2021-12-28 2023-04-11 四川好医生攀西药业有限责任公司 三肽在制备治疗和/或预防黏膜或皮肤损伤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2701281B2 (ja) * 1988-01-22 1998-01-21 吉富製薬株式会社 ピラゾロピリジン化合物
US20030162706A1 (en) * 2002-02-08 2003-08-28 The Procter & Gamble Company Angiogenesis modulating proteins
WO2003072061A2 (en) 2002-02-26 2003-09-04 Sangstat Medical Corporation Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy
CN1269837C (zh) 2002-09-02 2006-08-16 上海高科联合生物技术研发有限公司 一组合成抗菌肽
AU2006299682B2 (en) 2005-10-04 2013-09-05 Soligenix, Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
WO2008143679A2 (en) * 2006-06-01 2008-11-27 Verenium Corporation Nucleic acids and proteins and methods for making and using them
CN101578368A (zh) * 2006-10-04 2009-11-11 伊尼梅克斯制药公司 包括通过调节先天免疫治疗和预防感染在内的治疗和预防免疫相关疾病的新型肽
BRPI0717500A2 (pt) * 2006-10-04 2014-03-25 Inimex Pharmaceuticals Inc Peptídeos para o tratamento e a prevenção de desordens relacionadas à imunidade, incluindo tratamento e prevenção de infecção por modulação da imunidade inata.
CA2745930C (en) * 2008-12-08 2017-05-02 Soligenix, Inc. Topically active steroids for use in radiation and chemotherapeutics injury
IL225538A0 (en) * 2009-03-30 2013-06-27 Nestec Sa Methods for the identification of anti-immune reaction peptides of anti-citrullinates
CN102286073B (zh) * 2011-06-27 2013-09-11 华中科技大学同济医学院附属同济医院 一种与牙釉质表面轴向特异性结合的七肽及其应用
US20150148304A1 (en) * 2013-10-24 2015-05-28 Soligenix, Inc. Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation Syndrome
KR101742069B1 (ko) * 2013-10-25 2017-05-31 (주)연우 리필이 가능한 압출식 앰플용기

Also Published As

Publication number Publication date
AU2014318247B2 (en) 2018-05-24
FI3044229T3 (fi) 2023-12-14
BR112016005557A2 (pt) 2017-09-12
ES2965906T3 (es) 2024-04-17
HK1221960A1 (zh) 2017-06-16
AU2018214160A1 (en) 2018-08-30
LT3044229T (lt) 2024-01-25
CA2923553A1 (en) 2015-03-19
EP3044229B1 (en) 2023-10-04
MY177930A (en) 2020-09-28
NZ756128A (en) 2022-01-28
EP3044229A4 (en) 2017-04-19
CN105722852B (zh) 2021-03-05
US9850279B2 (en) 2017-12-26
CA2923553C (en) 2023-05-23
HUE066502T2 (hu) 2024-08-28
ZA201601967B (en) 2023-01-25
ZA202209308B (en) 2023-12-20
AU2018214160B2 (en) 2020-07-02
US20160229890A1 (en) 2016-08-11
BR112016005557B1 (pt) 2024-01-02
US10253068B2 (en) 2019-04-09
IL244573B (en) 2020-06-30
NZ718534A (en) 2019-09-27
KR102483333B1 (ko) 2022-12-29
HRP20231652T1 (hr) 2024-05-10
IL244573A0 (en) 2016-04-21
JP6645968B2 (ja) 2020-02-14
EP3044229A1 (en) 2016-07-20
KR20210117355A (ko) 2021-09-28
RU2016110153A (ru) 2017-10-16
MX2016003092A (es) 2016-11-14
US20180170964A1 (en) 2018-06-21
KR20210042417A (ko) 2021-04-19
JP2019142910A (ja) 2019-08-29
KR102304906B1 (ko) 2021-09-24
SG11201601891XA (en) 2016-04-28
WO2015038264A1 (en) 2015-03-19
PL3044229T3 (pl) 2024-03-25
AU2020203410A1 (en) 2020-06-11
RU2016110153A3 (pt) 2018-03-19
AU2014318247A1 (en) 2016-04-28
KR20160058845A (ko) 2016-05-25
RU2668963C2 (ru) 2018-10-05
DK3044229T3 (da) 2023-12-18
JP2016531145A (ja) 2016-10-06
CN105722852A (zh) 2016-06-29

Similar Documents

Publication Publication Date Title
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
HK1219435A1 (zh) 用於加速斑塊消退的組合物和治療方法
HUE052541T2 (hu) Immunogén WT-1 peptidek és eljárások azok alkalmazására
HK1221960A1 (zh) 用於治療口腔粘膜炎的新型肽和類似物
HK1219434A1 (zh) 用於加速斑塊消退的組合物和治療方法
HK1214838A1 (zh) 肽及包含它們的疫苗
HK1246694A1 (zh) α胸腺肽用於膿毒症治療的用途
SG11201507276UA (en) Improved methods of use for recombinant human secretoglobins
HK1223041A1 (zh) 匹多莫德用於治療炎症相關疾病的用途
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
HK1214511A1 (zh) 鹽酸蘭地洛爾在快速性心律失常的長期治療中的用途
GB201320506D0 (en) Cyclic amino compounds for the use in the treatment of cardiac disorders